Skye Bioscience, Inc. (SKYE)
USD 1.4
(-2.1%)
USD 1.4
(-2.1%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 11.94 Million USD | 31.05% |
| 2022 | 9.11 Million USD | -7.55% |
| 2021 | 9.85 Million USD | 268.87% |
| 2020 | 2.67 Million USD | 33.8% |
| 2019 | 1.99 Million USD | 2.02% |
| 2018 | 1.95 Million USD | 251.23% |
| 2017 | 557.21 Thousand USD | 72.32% |
| 2016 | 323.36 Thousand USD | -90.79% |
| 2015 | 3.51 Million USD | 907.92% |
| 2014 | 348.34 Thousand USD | 139.09% |
| 2013 | 145.69 Thousand USD | 239.74% |
| 2012 | 42.88 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 87.26 Million USD | -7.99% |
| 2024 Q1 | 94.83 Million USD | 694.24% |
| 2023 FY | 11.94 Million USD | 31.05% |
| 2023 Q4 | 11.94 Million USD | -23.48% |
| 2023 Q2 | 2.23 Million USD | -51.25% |
| 2023 Q1 | 4.58 Million USD | -49.66% |
| 2023 Q3 | 15.6 Million USD | 597.89% |
| 2022 Q4 | 9.11 Million USD | 217.59% |
| 2022 Q2 | 4.96 Million USD | -31.11% |
| 2022 Q1 | 7.21 Million USD | -26.83% |
| 2022 FY | 9.11 Million USD | -7.55% |
| 2022 Q3 | 2.86 Million USD | -42.25% |
| 2021 FY | 9.85 Million USD | 268.87% |
| 2021 Q3 | 11.68 Million USD | 112.95% |
| 2021 Q1 | 5.39 Million USD | 102.07% |
| 2021 Q2 | 5.48 Million USD | 1.66% |
| 2021 Q4 | 9.85 Million USD | -15.68% |
| 2020 FY | 2.67 Million USD | 33.8% |
| 2020 Q4 | 2.67 Million USD | -38.58% |
| 2020 Q3 | 4.34 Million USD | 1814.37% |
| 2020 Q2 | 227.2 Thousand USD | -66.24% |
| 2020 Q1 | 672.97 Thousand USD | -66.3% |
| 2019 Q3 | 1.72 Million USD | -43.99% |
| 2019 Q1 | 4.72 Million USD | 141.42% |
| 2019 FY | 1.99 Million USD | 2.02% |
| 2019 Q2 | 3.07 Million USD | -34.82% |
| 2019 Q4 | 1.99 Million USD | 15.75% |
| 2018 Q4 | 1.95 Million USD | 67.87% |
| 2018 FY | 1.95 Million USD | 251.23% |
| 2018 Q3 | 1.16 Million USD | -42.91% |
| 2018 Q2 | 2.04 Million USD | -35.33% |
| 2018 Q1 | 3.15 Million USD | 466.78% |
| 2017 Q4 | 557.21 Thousand USD | 62.45% |
| 2017 Q1 | 617.39 Thousand USD | 90.93% |
| 2017 Q2 | 484.04 Thousand USD | -21.6% |
| 2017 Q3 | 343 Thousand USD | -29.14% |
| 2017 FY | 557.21 Thousand USD | 72.32% |
| 2016 Q4 | 323.36 Thousand USD | -53.28% |
| 2016 FY | 323.36 Thousand USD | -90.79% |
| 2016 Q1 | 2.34 Million USD | -33.08% |
| 2016 Q2 | 1.08 Million USD | -53.99% |
| 2016 Q3 | 692.12 Thousand USD | -35.98% |
| 2015 Q2 | 820.79 Thousand USD | 75.11% |
| 2015 Q4 | 3.51 Million USD | -22.69% |
| 2015 Q3 | 4.54 Million USD | 453.31% |
| 2015 Q1 | 468.72 Thousand USD | 34.56% |
| 2015 FY | 3.51 Million USD | 907.92% |
| 2014 Q3 | 1.12 Million USD | 571.62% |
| 2014 Q4 | 348.34 Thousand USD | -69.06% |
| 2014 Q1 | 122.72 Thousand USD | -12.86% |
| 2014 FY | 348.34 Thousand USD | 139.09% |
| 2014 Q2 | 167.62 Thousand USD | 36.58% |
| 2013 Q2 | 128.99 Thousand USD | -4.0% |
| 2013 Q4 | 140.83 Thousand USD | -3.33% |
| 2013 FY | 145.69 Thousand USD | 239.74% |
| 2013 Q3 | 145.69 Thousand USD | 12.95% |
| 2013 Q1 | 134.36 Thousand USD | 0.0% |
| 2012 Q3 | 42.88 Thousand USD | 0.0% |
| 2012 FY | 42.88 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -516800.909% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -509.768% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -13.136% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -2062.648% |
| Rebus Holdings, Inc. | 5000.00 USD | -238708.22% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 90.83% |
| Qrons Inc. | 420.00 USD | -2842855.0% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1449.407% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 57.27% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -2384.702% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 69.263% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -65.385% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -15538.226% |
| SQZ Biotechnologies Company | 107.18 Million USD | 88.86% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -733.809% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -16400.257% |
| Mesoblast Limited | 667.9 Million USD | 98.212% |
| Marizyme, Inc. | 22.01 Million USD | 45.763% |
| Genus plc | 1.02 Billion USD | 98.839% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -779.036% |
| Pharming Group N.V. | 462.85 Million USD | 97.42% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -260.41% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -2292.681% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1804.372% |
| ContraFect Corporation | 20.67 Million USD | 42.258% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -2958.773% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -3024.314% |
| IMV Inc. | 31.33 Million USD | 61.893% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -187.997% |
| MultiCell Technologies, Inc. | 126.22 USD | -9459899.208% |
| ONE Bio Corp. | 70.08 Million USD | 82.963% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -1170.677% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 90.709% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -2665.815% |
| Q BioMed Inc. | 3.51 Million USD | -239.649% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 66.058% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -4470.02% |
| Biomind Labs Inc. | 73.81 Thousand USD | -16075.254% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 97.325% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -724.134% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 60.218% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -334.776% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1636.822% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -358.683% |
| GB Sciences, Inc. | 103.44 Thousand USD | -11443.098% |
| Alpha Cognition Inc. | 2.45 Million USD | -386.932% |
| HST Global, Inc. | 1526.00 USD | -782364.679% |
| CSL Limited | 38.02 Billion USD | 99.969% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1108.584% |
| Halberd Corporation | 10.13 Thousand USD | -117760.142% |
| Enzolytics Inc. | 361.7 Million USD | 96.699% |
| Agentix Corp. | 261.39 Thousand USD | -4468.009% |
| Resverlogix Corp. | 8.11 Million USD | -47.14% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -535.845% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.737% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 74.969% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1766.693% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -52313.902% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -33.425% |
| AVAX Technologies, Inc. | 7.37 Million USD | -61.857% |
| Zenith Capital Corp. | 7410.00 USD | -161039.15% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.647% |
| Ember Therapeutics, Inc. | 184.00 USD | -6489253.804% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -3610.438% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -4468.499% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1186.736% |
| Kadimastem Ltd | 2.3 Million USD | -418.229% |
| Helix BioMedix, Inc. | 3.02 Million USD | -294.713% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 77.343% |
| BioStem Technologies, Inc. | 14.56 Million USD | 17.993% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -20813.6% |
| LadRx Corporation | 2.3 Million USD | -417.375% |
| Cell Source, Inc. | 195.17 Thousand USD | -6017.923% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -3276.651% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -3276.651% |
| NovAccess Global Inc. | 62.24 Thousand USD | -19081.999% |
| Affymax, Inc. | 7.44 Million USD | -60.425% |
| Itoco Inc. | 1.4 Million USD | -752.843% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -12382.527% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -11164.539% |
| Mobile Lads Corp. | 52.00 USD | -22962228.846% |
| CytoDyn Inc. | 11.13 Million USD | -7.224% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -8251.573% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -66680.822% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -2997.616% |
| SYBLEU INC | 330.46 Thousand USD | -3513.182% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -2816.407% |
| International Stem Cell Corporation | 5.39 Million USD | -121.529% |
| Bioxytran, Inc. | 137.63 Thousand USD | -8575.228% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 20.407% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 27.979% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -15014.444% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -1280.91% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -58.845% |
| Neutra Corp. | 2851.00 USD | -418714.837% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 63.154% |
| PureTech Health plc | 693.97 Million USD | 98.279% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -47.941% |
| IXICO plc | 15.84 Million USD | 24.637% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -44.173% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 88.444% |
| CSL Limited | 38.02 Billion USD | 99.969% |
| Cellectis S.A. | 333.99 Million USD | 96.425% |